A Single-Center Retrospective Observational Study Evaluating the Favorable Predictive Factors for the Disease Control Time of Treatment with Tocilizumab in Patients of Rheumatoid Arthritis
Nobuyasu Ishii, Toshiki Shimizu, Yoshihisa Ishiura, Hideki Amuro, Tohru Nishizawa, Takeshi Tamaki, Shosaku Nomura First Department of Internal Medicine, Kansai Medical University, Moriguchi-City, Osaka, 570-8507, JapanCorrespondence: Toshiki ShimizuFirst Department of Internal Medicine, Kansai Medic...
Guardado en:
Autores principales: | Ishii N, Shimizu T, Ishiura Y, Amuro H, Nishizawa T, Tamaki T, Nomura S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bbf04dc6e3cf4f208dbc2956ed662950 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years
por: Farah Z, et al.
Publicado: (2016) -
Safety and efficacy of tocilizumab for rheumatoid arthritis: a systematic review and metaanalysis of clinical trial studies
por: Amal Saki, et al.
Publicado: (2021) -
Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
por: Cimmino MA, et al.
Publicado: (2020) -
Value of Platelet Distribution Width and Mean Platelet Volume in Disease Activity Score of Rheumatoid Arthritis
por: Khaled SAA, et al.
Publicado: (2020) -
The Relationship between Platelet Indices and Ultrasound, Clinical, Laboratory Parameters of Disease Activity in Patients with Rheumatoid Arthritis
por: Bożena Targońska-Stępniak, et al.
Publicado: (2021)